ALIMTA

LOE Approaching

pemetrexed disodium

Eli Lilly and Company

NDAINTRAVENOUSPOWDERPriority Review

Approved

Feb 2004

Lifecycle

LOE Approaching

Competitive Pressure

30/100

Clinical Trials

163

Mechanism of Action

folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis…

Indications (2)

non-small cell lung cancer lung cancer

Clinical Trials (5)

NCT06607185Phase 1Active Not Recruiting

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Started Oct 2024

750 enrolled

Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerColorectal Cancer+2 more

NCT06561685Phase 1Recruiting

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Started Sep 2024

340 enrolled

Metastatic Solid TumorAdvanced Solid TumorNon-small Cell Lung Cancer+1 more

NCT06119581Phase 3Recruiting

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Started Dec 2023

1,264 enrolled

Carcinoma, Non-Small-Cell LungNeoplasm Metastasis

NCT04956640Phase 1/2Recruiting

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Started Jul 2021

540 enrolled

Carcinoma, Non-Small-Cell LungColorectal NeoplasmsEndometrial Neoplasms+3 more

NCT04194944Phase 3Active Not Recruiting

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Started Feb 2020

261 enrolled